-- 周一,英国股市收跌,富时100指数下跌0.56%,投资者在即将公布的企业财报和包括英国央行在内的关键央行利率决议前保持谨慎。 丹麦银行表示:“尽管近期数据表现强劲,但英国劳动力市场依然疲软,3.75%的基准利率远高于2022年的水平。加息必须权衡其可能加剧经济萎缩的巨大风险。我们认为,英国央行在可预见的未来很可能继续按兵不动。” 与此同时,英国工业联合会(CBI)分销贸易调查显示,4月份零售销售收支平衡指数从3月份的-52%降至-68%。据Investing.com报道,市场普遍预期该月收支平衡指数为-42%。 “随着伊朗冲突的经济影响日益明朗,企业将期待政府认识到,缓解生活成本压力取决于解决企业运营成本问题。对于分销行业而言,这意味着要确保《就业权利法案》的适用范围合理,进行切实有效的商业税率改革,并进一步探索如何从电费中剔除非能源政策成本,”英国工业联合会(CBI)首席经济学家马丁·萨托里乌斯表示。 在公司新闻方面,葛兰素史克(GSK.L)股价下跌0.20%,本周开局繁忙。除了与Alfasigma公司就其胆汁淤积性瘙痒治疗药物linerixibat达成许可协议外,这家英国制药巨头还分别在美国和欧洲获得了其每月一次的在研肝病治疗药物efimosfermin的突破性疗法认定和优先药物认定。 与此同时,美国特拉华州衡平法院批准了 AnaptysBio 对 GSK 子公司 Tesaro 提出的驳回动议,后者重申其观点,即预期违约索赔完全没有依据。
Related Articles
Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set
Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.